Devin W. Smith - 02 Apr 2025 Form 4 Insider Report for IO Biotech, Inc. (IOBT)

Reporting relationship: General Counsel
Issuer ticker: IOBT
Reported as of: 02 Apr 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Apr 2025, 16:13:48 UTC
Prior SEC filing: 23 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Brian Burkavage, Attorney-in-Fact for Devin W. Smith

Key filing fact

Devin W. Smith filed Form 4 for IO Biotech, Inc. (IOBT) on 04 Apr 2025.

Key facts

This page summarizes Devin W. Smith's Form 4 filing for IO Biotech, Inc. (IOBT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Apr 2025, 16:13.

Change

Previous filing in this sequence was filed on 23 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IOBT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +140,000
Change %
Price: $0.000000
Shares after: 140,000
Date: 02 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 140,000
Exercise price: $1.07
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One-fourth of these options vest on April 2, 2026, and 1/36th of the remaining options vest each month thereafter, subject to the reporting person's continued service through the applicable vesting date, and subject to 25% acceleration upon termination of service by the issuer without cause and 100% acceleration upon termination of service by the Issuer without cause if such termination occurs within 24 months of a change of control.